| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Viridian Therapeutics, Inc.\de (VRDN) has 8 insiders with recent SEC Form 4 filings, including 4 buys and 11 sells. VRDN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.91M | $64.69M | - | |
| Dir | 21.0K | $347.0K | - | |
| Dir | 21.0K | $347.0K | - | |
| Dir | 21.0K | $347.0K | - | |
| Dir | 21.0K | $347.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2018 | Levy Adam Scott | Chief Business Officer | Buy | 9,090 | $5.50 | $49,995.00 | +626.9% | |
| Dec 20, 2017 | Hughes Thomas E. | Director | Sell | 12,000 | $8.00 | $96,000.00 | -80.9% | |
| Jun 22, 2017 | Levy Adam Scott | Chief Business Officer | Buy | 200 | $7.55 | $1,510.00 | New | |
| Mar 10, 2017 | Lefkoff Kyle | Director | Sell | 5,800 | $14.34 | $83,190.44 | -0.6% | |
| Mar 8, 2017 | Lefkoff Kyle | Director | Sell | 15,000 | $15.40 | $230,977.44 | -1.0% | |
| Feb 28, 2017 | Lefkoff Kyle | Director | Sell | 10,258 | $13.89 | $142,518.79 | -0.7% | |
| Feb 23, 2017 | Lefkoff Kyle | Director | Sell | 5,902 | $14.14 | $83,451.71 | -0.6% | |
| Nov 20, 2015 | Riccitelli Samuel D | President &CEO | Buy | 14,000 | $0.79 | $11,060.00 | +2.1% |